Pfizer Inc. (PFE)
NYSE: PFE · IEX Real-Time Price · USD
29.56
-0.41 (-1.38%)
Jul 22, 2024, 11:41 AM EDT - Market open
Pfizer Employees
Pfizer had 88,000 employees as of December 31, 2023. The number of employees increased by 5,000 or 6.02% compared to the previous year.
Employees
88,000
Change (1Y)
5,000
Growth (1Y)
6.02%
Revenue / Employee
$626,068
Profits / Employee
-$3,511
Market Cap
168.27B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 88,000 | 5,000 | 6.02% |
Dec 31, 2022 | 83,000 | 4,000 | 5.06% |
Dec 31, 2021 | 79,000 | 500 | 0.64% |
Dec 31, 2020 | 78,500 | -9,800 | -11.10% |
Dec 31, 2019 | 88,300 | -4,100 | -4.44% |
Dec 31, 2018 | 92,400 | 2,200 | 2.44% |
Dec 31, 2017 | 90,200 | -6,300 | -6.53% |
Dec 31, 2016 | 96,500 | -1,400 | -1.43% |
Dec 31, 2015 | 97,900 | 19,600 | 25.03% |
Dec 31, 2014 | 78,300 | 600 | 0.77% |
Dec 31, 2013 | 77,700 | -13,800 | -15.08% |
Dec 31, 2012 | 91,500 | -12,200 | -11.76% |
Dec 31, 2011 | 103,700 | -6,900 | -6.24% |
Dec 31, 2010 | 110,600 | -5,900 | -5.06% |
Dec 31, 2009 | 116,500 | 34,700 | 42.42% |
Dec 31, 2008 | 81,800 | -4,800 | -5.54% |
Dec 31, 2007 | 86,600 | -11,400 | -11.63% |
Dec 31, 2006 | 98,000 | -8,000 | -7.55% |
Dec 31, 2005 | 106,000 | -9,000 | -7.83% |
Dec 31, 2004 | 115,000 | -7,000 | -5.74% |
Dec 31, 2003 | 122,000 | 24,000 | 24.49% |
Dec 31, 2002 | 98,000 | 8,000 | 8.89% |
Dec 31, 2001 | 90,000 | 0 | - |
Dec 31, 2000 | 90,000 | 39,100 | 76.82% |
Dec 31, 1999 | 50,900 | 4,500 | 9.70% |
Dec 31, 1998 | 46,400 | -2,800 | -5.69% |
Dec 31, 1997 | 49,200 | 2,700 | 5.81% |
Dec 31, 1996 | 46,500 | 2,700 | 6.16% |
Dec 31, 1995 | 43,800 | 3,000 | 7.35% |
Dec 31, 1994 | 40,800 | 300 | 0.74% |
Dec 31, 1993 | 40,500 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
Elevance Health | 104,900 |
Sanofi | 86,088 |
Novartis AG | 76,057 |
Danaher | 63,000 |
Amgen | 26,700 |
Stryker | 26,700 |
PFE News
- 3 days ago - Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026 - Benzinga
- 4 days ago - Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio - Benzinga
- 4 days ago - Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion - GlobeNewsWire
- 5 days ago - Nvidia, Pfizer lead $80 mln funding for Israeli medical AI tech firm CytoReason - Reuters
- 5 days ago - European Commission didn't provide enough information about COVID-19 vaccine deals, EU court says - Market Watch
- 9 days ago - With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs - Benzinga
- 10 days ago - Pfizer moves forward with once-daily weight-loss pill to compete with Wegovy - New York Post
- 10 days ago - Pfizer Stock Rises as Company Advances Studies of Once-a-Day Weight-Loss Pill - Investopedia